Matthew W. Emmens

2011

In 2011, Matthew W. Emmens earned a total compensation of $13.4M as Former Chairman, President CEO at Vertex Pharmaceuticals, a 10% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,019,587
Option Awards$7,343,482
Salary$1,163,068
Stock Awards$1,830,927
Other$1,470
Total$13,358,534

Emmens received $7.3M in option awards, accounting for 55% of the total pay in 2011.

Emmens also received $3M in non-equity incentive plan, $1.2M in salary, $1.8M in stock awards and $1.5K in other compensation.

Rankings

In 2011, Matthew W. Emmens' compensation ranked 193rd out of 10,747 executives tracked by ExecPay. In other words, Emmens earned more than 98.2% of executives.

ClassificationRankingPercentile
All
193
out of 10,747
98th
Division
Manufacturing
61
out of 3,958
99th
Major group
Chemicals And Allied Products
18
out of 1,031
98th
Industry group
Drugs
10
out of 779
99th
Industry
Pharmaceutical Preparations
9
out of 567
98th
Source: SEC filing on April 4, 2013.

Emmens' colleagues

We found four more compensation records of executives who worked with Matthew W. Emmens at Vertex Pharmaceuticals in 2011.

2011

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2011

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

2011

Nancy Wysenski

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2011

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

In-depth

You may also like